Relative Timing Between Kappa Opioid Receptor Activation and Cocaine Determines the Impact on Reward and Dopamine Release

Neuropsychopharmacology

Volumn 41, Issue 4, 2016, Pages 989-1002

  Chartoff, Elena H ^a   Ebner, Shayla R ^b   Sparrow, Angela ^a   Potter, David ^a   Baker, Phillip M ^b   Ragozzino, Michael E ^b   Roitman, Mitchell F ^b  

^a MCLEAN HOSPITAL   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COCAINE; DOPAMINE; DOPAMINE TRANSPORTER; KAPPA OPIATE RECEPTOR; MESSENGER RNA; PRODYNORPHIN; SALVINORIN A; TYROSINE 3 MONOOXYGENASE; CLERODANE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; BRAIN DEPTH STIMULATION; COMPARATIVE STUDY; CONTROLLED STUDY; CYCLIC POTENTIOMETRY; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; GENE EXPRESSION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; REWARD; VENTRAL TEGMENTUM; AFFECT; AGONISTS; ANIMAL; DRUG EFFECTS; GENETICS; METABOLISM; NUCLEUS ACCUMBENS; PHYSIOLOGY; SELF STIMULATION; SPRAGUE DAWLEY RAT; TIME FACTOR;

AFFECT; ANIMALS; COCAINE; DITERPENES, CLERODANE; DOPAMINE; MALE; NUCLEUS ACCUMBENS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; REWARD; SELF STIMULATION; TIME FACTORS; VENTRAL TEGMENTAL AREA;

EID: 84957847011     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.226     Document Type: Article

References (70)

1. Aldrich JV, McLaughlin JP (2009). Peptide kappa opioid receptor ligands: Potential for drug development. AAPS 11: 312-322.
2. Aldrich JV, Patkar KA, McLaughlin JP (2009). Zyklophin, a systemically active selective kappa opioid receptor peptide antagonist with short duration of action. Proc Natl Acad Sci U S A 106: 18396-18401.
3. Bals-Kubik R, Ableitner A, Herz A, Shippenberg TS (1993). Neuroanatomical sites mediating the motivational effects of opioids as mapped by the conditioned place preference paradigm in rats. J Pharmacol Exp Ther 264: 489-495.
4. Beardsley PM, Howard JL, Shelton KL, Carroll FI (2005). Differential effects of the novel kappa opioid receptor antagonist, jdtic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats. Psychopharmacology (Berl) 183: 118-126.
5. Beguin C, Duncan KK, Munro TA, Ho DM, Xu W, Liu-Chen LY et al (2009). Modification of the furan ring of salvinorin a: Identification of a selective partial agonist at the kappa opioid receptor. Bioorg Med Chem 17: 1370-1380.
6. Beguin C, Potter DN, Dinieri JA, Munro TA, Richards MR, Paine TA et al (2008). N-methylacetamide analog of salvinorin a: A highly potent and selective kappa-opioid receptor agonist with oral efficacy. J Pharmacol Exp Ther 324: 188-195.
7. Bruchas MR, Chavkin C (2010). Kinase cascades and liganddirected signaling at the kappa opioid receptor. Psychopharmacology (Berl) 210: 137-147.
8. Bruchas MR, Land BB, Chavkin C (2010). The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res 1314: 44-55.
9. Carlezon WA Jr (2003). Place conditioning to study drug reward and aversion. Methods Mol Med 84: 243-249.
10. Carlezon WA Jr, Beguin C, Dinieri JA, Baumann MH, Richards MR, Todtenkopf MS et al (2006). Depressive-like effects of the kappa-opioid receptor agonist salvinorin a on behavior and neurochemistry in rats. J Pharmacol Exp Ther 316: 440-447.
11. Carlezon WA Jr, Chartoff EH (2007). Intracranial self-stimulation (icss) in rodents to study the neurobiology of motivation. Nat Protoc 2: 2987-2995.
12. Carlezon WAJ, Bèguin C, Knoll AT, Cohen BM (2009). Kappa-opioid ligands in the study and treatment of mood disorders. Pharmacol Ther 123: 334-343.
13. Chartoff E, Sawyer A, Rachlin A, Potter D, Pliakas A, Carlezon WA (2012). Blockade of kappa opioid receptors attenuates the development of depressive-like behaviors induced by cocaine withdrawal in rats. Neuropharmacology 62: 167-176.
14. Chartoff EH, Potter D, Damez-Werno D, Cohen BM, Carlezon WA Jr (2008). Exposure to the selective kappa-opioid receptor agonist salvinorin a modulates the behavioral and molecular effects of cocaine in rats. Neuropsychopharmacology 33: 2676-2687.
15. Cheer JF, Wassum KM, Heien MLAV, Phillips PEM, Wightman RM (2004). Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci 24: 4393-4400.
16. Cheer JF, Wassum KM, Wightman MR (2006). Cannabinoid modulation of electrically evoked ph and oxygen transients in the nucleus accumbens of awake rats. J Neurochem 97: 1145-1154.
17. Cole RL, Konradi C, Douglass J, Hyman SE (1995). Neuronal adaptation to amphetamine and dopamine: Molecular mechanisms of prodynorphin gene regulation in rat striatum. Neuron 14: 813-823.
18. Cone JJ, Chartoff EH, Potter DN, Ebner SR, Roitman MF (2013). Prolonged high fat diet reduces dopamine reuptake without altering dat gene expression. PLoS One 8: e58251.
19. Di Chiara G, Imperato A (1988). Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244: 1067-1080.
20. Ebner SR, Roitman MF, Potter DN, Rachlin AB, Chartoff EH (2010). Depressive-like effects of the kappa opioid receptor agonist salvinorin a are associated with decreased phasic dopamine release in the nucleus accumbens. Psychopharmacology (Berl) 210: 241-252.
21. Ehrich JM, Phillips PE, Chavkin C (2014). Kappa opioid receptor activation potentiates the cocaine-induced increase in evoked dopamine release recorded in vivo in the mouse nucleus accumbens. Neuropsychopharmacology 39: 3036-3048.
22. Fortin SM, Cone JJ, Ng-Evans S, McCutcheon JE, Roitman MF (2015). Sampling phasic dopamine signaling with fast-scan cyclic voltammetry in awake, behaving rats. Curr Protoc Neurosci 70: 7 25 21-27 25 20.
23. Fuentealba JA, Gysling K, Magendzo K, Andres ME (2006). Repeated administration of the selective kappa-opioid receptor agonist u-69593 increases stimulated dopamine extracellular levels in the rat nucleus accumbens. J Neurosci Res 84: 450-459.
24. Gerfen CR (2000). Molecular effects of dopamine on striatalprojection pathways. Trends Neurosci 23: S64-S70.
25. Grant BF, Stinson FS, Dawson DA, Chou SP, Dufour MC, Compton W et al (2004). Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry 61: 807-816.
26. Graziane NM, Polter AM, Briand LA, Pierce RC, Kauer JA (2013). Kappa opioid receptors regulate stress-induced cocaine seeking and synaptic plasticity. Neuron 77: 942-954.
27. Heidbreder CA, Schenk S, Partridge B, Shippenberg TS (1998). Increased responsiveness of mesolimbic and mesostriatal dopamine neurons to cocaine following repeated administration of a selective kappa-opioid receptor agonist. Synapse 30: 255-262.
28. Heien ML, Johnson MA, Wightman RM (2004). Resolving neurotransmitters detected by fast-scan cyclic voltammetry. Anal Chem 76: 5697-5704.
29. Hurd YL, Herkenham M (1993). Molecular alterations in the neostriatum of human cocaine addicts. Synapse 13: 357-369.
30. Jackson K, Carroll FI, Negus S, Damaj M (2010). Effect of the selective kappa-opioid receptor antagonist jdtic on nicotine antinociception, reward, and withdrawal in the mouse. Psychopharmacology (Berl) 210: 285-294.
31. Kimmel HL, Carroll FI, Kuhar MJ (2000). Dopamine transporter synthesis and degradation rate in rat striatum and nucleus accumbens using rti-76. Neuropharmacology 39: 578-585.
32. Kivell BM, Ewald AW, Prisinzano TE (2014). Salvinorin a analogs and other kappa-opioid receptor compounds as treatments for cocaine abuse. Adv Pharmacol 69: 481-511.
33. Knoll AT, Carlezon WA Jr (2010). Dynorphin, stress, and depression. Brain Res 1314: 56-73.
34. Knoll AT, Meloni EG, Thomas JB, Carroll FI, Carlezon WA Jr (2007). Anxiolytic-like effects of kappa-opioid receptor antagonists in models of unlearned and learned fear in rats. J Pharmacol Exp Ther 323: 838-845.
35. Koob GF, Le Moal M (2008). Addiction and the brain antireward system. Annu Rev Psychol 59: 29-53.
36. Lindgren N, Goiny M, Herrera-Marschitz M, Haycock JW, Hökfelt T, Fisone G (2002). Activation of extracellular signalregulated kinases 1 and 2 by depolarization stimulates tyrosine hydroxylase phosphorylation and dopamine synthesis in rat brain. Eur J Neurosci 15: 769-773.
37. Liu-Chen LY (2004). Agonist-induced regulation and trafficking of kappa opioid receptors. Life Sci 75: 511-536.
38. Lu L, Grimm JW, Shaham Y, Hope BT (2003). Molecular neuroadaptations in the accumbens and ventral tegmental area during the first 90 days of forced abstinence from cocaine selfadministration in rats. J Neurochem 85: 1604-1613.
39. Mague SD, Pliakas AM, Todtenkopf MS, Tomasiewicz HC, Zhang Y, Stevens WC Jr et al (2003). Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther 305: 323-330.
40. McLaughlin JP, Land BB, Li S, Pintar JE, Chavkin C (2006). Prior activation of kappa opioid receptors by u50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology 31: 787-794.
41. McLaughlin JP, Marton-Popovici M, Chavkin C (2003). Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci 23: 5674-5683.
42. Mello NK, Negus SS (2000). Interactions between kappa opioid agonists and cocaine: preclinical studies. Annals NY Acad Sci 909: 104-132.
43. Negus SS (2004). Effects of the kappa opioid agonist u50,488 and the kappa opioid antagonist nor-binaltorphimine on choice between cocaine and food in rhesus monkeys. Psychopharmacology (Berl) 176: 204-213.
44. Negus SS, Mello NK, Portoghese PS, Lin CE (1997). Effects of kappa opioids on cocaine self-administration by rhesus monkeys. J Pharmacol Exp Ther 282: 44-55.
45. Nemeth CL, Paine TA, Rittiner JE, Beguin C, Carroll FI, Roth BL et al (2010). Role of kappa-opioid receptors in the effects of salvinorin a and ketamine on attention in rats. Psychopharmacology (Berl) 210: 263-274.
46. Newton SS, Thome J, Wallace TL, Shirayama Y, Schlesinger L, Sakai N et al (2002). Inhibition of camp response elementbinding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J Neurosci 22: 10883-10890.
47. Paxinos G, Watson C (1996). The Rat Brain in Stereotaxic Coordinates. Academic Press.
48. Phillips PEM, Stuber GD, Heien ML, Wightman RM, Carelli RM (2003). Subsecond dopamine release promotes cocaine seeking. Nature 422: 614-618.
49. Pliakas AM, Carlson RR, Neve RL, Konradi C, Nestler EJ, Carlezon WA Jr (2001). Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated camp response element-binding protein expression in nucleus accumbens. J Neurosci 21: 7397-7403.
50. Potter DN, Damez-Werno D, Carlezon WA Jr, Cohen BM, Chartoff EH (2011). Repeated exposure to the kappa-opioid receptor agonist salvinorin a modulates extracellular signalregulated kinase and reward sensitivity. Biol Psychiatry 70: 744-753.
51. Pravetoni M, Pentel PR, Potter DN, Chartoff EH, Tally L, LeSage MG (2014). Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats. PLoS One 9: e101807.
52. Redila V, Chavkin C (2008). Stress-induced reinstatement of cocaine seeking is mediated by the kappa opioid system. Psychopharmacology (Berl) 200: 59-70.
53. Roitman MF, Stuber GD, Phillips PE, Wightman RM, Carelli RM (2004). Dopamine operates as a subsecond modulator of food seeking. J Neurosci 24: 1265-1271.
54. Russell SE, Rachlin AB, Smith KL, Muschamp J, Berry L, Zhao Z et al (2014). Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist u-50488 in rats. Biol Psychiatry 176: 213-222.
55. Schenk S, Partridge B, Shippenberg TS (1999). U69593, a kappaopioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking. Psychopharmacology (Berl) 144: 339-346.
56. Schindler AG, Li S, Chavkin C (2010). Behavioral stress may increase the rewarding valence of cocaine-associated cues through a dynorphin/kappa-opioid receptor-mediated mechanism without affecting associative learning or memory retrieval mechanisms. Neuropsychopharmacology 35: 1932-1942.
57. Shippenberg TS (2009). The dynorphin/kappa opioid receptor system: A new target for the treatment of addiction and affective disorders[quest]. Neuropsychopharmacology 34: 247-247.
58. Shippenberg TS, Zapata A, Chefer VI (2007). Dynorphin and the pathophysiology of drug addiction. Pharmacol Ther 116: 306-321.
59. Solomon RL, Corbit JD (1974). An opponent-process theory of motivation: I. Temporal dynamics of affect. Psychol Rev 81: 119-145.
60. Son JH, Latimer C, Keefe KA (2011). Impaired formation of stimulus-response, but not action-outcome, associations in rats with methamphetamine-induced neurotoxicity. Neuropsychopharmacology 36: 2441-2451.
61. Spanagel R, Herz A, Shippenberg TS (1992). Opposing tonically active endogenous opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A 89: 2046-2050.
62. Svingos AL, Chavkin C, Colago EE, Pickel VM (2001). Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse 42: 185-192.
63. Terman GW, Wagner JJ, Chavkin C (1994). Kappa opioids inhibit induction of long-term potentiation in the dentate gyrus of the guinea pig hippocampus. J Neurosci 14: 4740-4747.
64. Tomasiewicz HC, Todtenkopf MS, Chartoff EH, Cohen BM, Carlezon WA Jr. (2008). The kappa-opioid agonist u69,593 blocks cocaine-induced enhancement of brain stimulation reward. Biol Psychiatry 64: 982-988.
65. Van't Veer A, Carlezon WA Jr (2013). Role of kappa-opioid receptors in stress and anxiety-related behavior. Psychopharmacology (Berl) 229: 435-452.
66. Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R et al (1997). Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature 386: 830-833.
67. Walker BM, Koob GF (2007). Pharmacological evidence for a motivational role of [kappa]-opioid systems in ethanol dependence. Neuropsychopharmacology 33: 643-652.
68. Wee S, Orio L, Ghirmai S, Cashman J, Koob G (2009). Inhibition of kappa opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine. Psychopharmacology (Berl) 205: 565-575.
69. Weiss F, Paulus MP, Lorang MT, Koob GF (1992). Increases in extracellular dopamine in the nucleus accumbens by cocaine are inversely related to basal levels: Effects of acute and repeated administration. J Neurosci 12: 4372-4380.
70. Xia YF, He L, Whistler JL, Hjelmstad GO (2008). Acute amphetamine exposure selectively desensitizes kappa-opioid receptors in the nucleus accumbens. Neuropsychopharmacology 33: 892-900.